Robin D. Harrington

Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial.

David J. Sims, R. Simon, L. Rubinstein, 2016, The Journal of molecular diagnostics : JMD.

Circulating tumor DNA sequencing provides comprehensive mutation profiling for pediatric central nervous system tumors

P. M. Williams, S. Mueller, R. Packer, 2022, npj Precision Oncology.

Certified DNA Reference Materials to Compare HER2 Gene Amplification Measurements Using Next-Generation Sequencing Methods.

David J. Sims, S. Lund, J. Almeida, 2016, The Journal of molecular diagnostics : JMD.

Plasmid-Based Materials as Multiplex Quality Controls and Calibrators for Clinical Next-Generation Sequencing Assays.

Robin D Harrington, Chih-Jian Lih, Courtney H Bouk, 2016, The Journal of molecular diagnostics : JMD.

Design and development of the molecular analysis for Therapy Choice (NCI-MATCH) Designated Laboratory Network.

A. Iafrate, J. Sklar, K. Flaherty, 2019, Journal of Clinical Oncology.

Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial.

Lisa M McShane, Robin D Harrington, Chih-Jian Lih, 2017, The Journal of molecular diagnostics : JMD.

Feasibility of molecular profiling based assignment of cancer treatment (MPACT): A randomized NCI precision medicine study.

David J. Sims, R. Simon, L. Rubinstein, 2016 .